Lantern Pharma Says Zirdafulven Phase 1b/2 Trial in Bladder Cancer Cleared by European Medicines Agency

RegulatoryZirdafulvenPositive

AI Analysis

Summary

Lantern Pharma announced that its Phase 1b/2 trial of Zirdafulven for bladder cancer has received clearance from the European Medicines Agency. This regulatory approval allows the company to proceed with the clinical trial in Europe.

Clinical Trial Data

Phase

1b/2

Outcome Details

Phase 1b/2 trial cleared by European Medicines Agency

Importance:6/10

Sentiment:

0.70

bladder cancerEMA clearanceclinical trialzirdafulven

Related Companies

$LTRN

Read the original article

Published by yahoo_finance on July 28, 2026 12:35 PM

Read Original